stockrow
Friday 6 November 2026
Export PLSE’s income statement to Excel — free account
Pulse Biosciences, Inc
PLSE Healthcare Medical Instruments & Supplies
Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022.
- Revenue
- +359.3%
- EPS
- −10.3%
- Free cash flow
- −1,180.5%
Quarter to September 2026, against a year earlier
52.29
0.78
−1.47%
Follow PLSE
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2,403.42 | 1,619.34 | 1,978.44 | 1,526.95 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(235.10) | (102.57) | (100.58) | (62.71) | |
P/B ratio |
19.56 | 19.29 | 22.14 | 11.47 | |
Price to Tangible BV |
19.87 | 19.89 | 23.27 | 11.97 | |
EV/Sales |
2,422.88 | 1,589.11 | 1,975.05 | 1,502.31 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(57.16) | (30.82) | (26.55) | (16.82) | |
EV/FCF |
(16.75) | (30.68) | (26.41) | (16.72) | |
Quick Ratio |
2.76 | 9.27 | 6.99 | 10.22 | |
Current Ratio |
14.35 | 9.63 | 7.26 | 10.53 | |
Net Debt/EBITDA |
0.00 | 4.06 | 3.62 | 4.49 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.66 | 0.76 | 0.79 | 0.85 | |
Capex/Depreciation |
0.00 | (0.35) | (0.13) | (0.41) | |
Research and Development Expense of Revenue |
4,265.32% | 3,911.52% | 3,139.65% | 4,139.02% | |
Selling, General and Administrative Expense of Revenue |
1,936.20% | 1,948.62% | 1,643.64% | 2,776.52% | |
Intangible Assets out of Total Assets |
0.01 | 0.03 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
1,344.81% | 1,145.85% | 476.81% | 1,882.58% | |
Graham Net Nets |
0.05 | 0.05 | 0.04 | 0.08 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.42%) | (4.26%) | (5.09%) | (7.87%) | |
Free Cash Flow Yield |
(6.02%) | (3.20%) | (3.78%) | (5.88%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.00 | |
Operating CF per Share |
(0.21) | (0.27) | (0.21) | (0.22) | |
Capex per Share |
(2.12) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.33) | (0.27) | (0.22) | (0.22) | |
Cash per Share |
0.51 | 1.47 | 1.00 | 1.20 | |
Shareholders Equity per Share |
2.55 | 1.44 | 0.98 | 1.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.55 | 1.44 | 0.98 | 1.20 | |
Free Cash Flow |
(167.76) | (18.80) | (14.63) | (14.86) | |
Working Capital |
178.81 | 94.72 | 61.33 | 75.50 | |
Capital Expenditures |
(152.49) | (0.09) | (0.03) | (0.10) | |
Net Current Asset Value |
174.20 | 89.64 | 55.81 | 69.54 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
386.05 | 0.21 | 0.08 | 0.40 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.16 | 0.06 | 0.08 | 0.15 | |
Average Payables |
3.00 | 2.79 | 2.57 | 2.23 | |
Average Inventory |
0.14 | 0.14 | 0.12 | 0.44 | |
Average Assets |
155.17 | 117.91 | 107.50 | 113.50 | |
Average Common Equity |
138.13 | 101.99 | 92.38 | 97.76 |
Columns are period end dates · fundamentals updated 5 Nov 2026